cytochrome-c-t has been researched along with Endometrial-Hyperplasia* in 2 studies
2 other study(ies) available for cytochrome-c-t and Endometrial-Hyperplasia
Article | Year |
---|---|
Chloroform Fraction of
The diagnosis of uterine dysfunction (endometrial hyperplasia) is on the rise. The available treatment is quite expensive and associated with some side effects. The therapeutic potential of natural products is now being explored, as they are easily available with little or no side effects.. This study aims to investigate the potential therapeutic effect of chloroform fraction of methanol extract of. Thirty-six rats were randomly divided equally into six groups. These included control group, CFDC: (100 mg/kg), CFDC: (200 mg/kg), EB: (2 mg/kg), EB + CFDC (100 mg/kg), and EB + CFDC (200 mg/kg). Endometrial hyperplasia (EH) was induced by intraperitoneal injection of EB. The levels of estrogen (E2), progesterone (PG), Follicle stimulating hormone (FSH), Luteinizing hormone (LH), Malondialdehyde (MDA), Superoxide dismutase (SOD), and Glutathione peroxidase (GSH-Px) activities were determined using ELISA technique. The uterine histological assessment and immunohistochemical expression levels of estrogen receptor, Ki-67, cytochrome c, and caspase 3 were carried out.. EH was severely expressed in the uterine section of EB-treated rats. However, CFDC administration improved the pathological features of the animal model. The sex hormones levels were increased in the EB-treated group, which were significantly reduced by CFDC. The antioxidant indices were also restored by CFDC. Immunoexpression levels of ERα and Ki-67 were downregulated while cytochrome c and caspase 3 were upregulated by CFDC.. This study suggests that CFDC contains phytochemicals that can protect against EB-induced EH via modulation of hormonal signaling, apoptotic machinery, and oxidative indices. Topics: Animals; Antioxidants; Caspase 3; Chloroform; Cytochromes c; Endometrial Hyperplasia; Estradiol; Female; Humans; Ki-67 Antigen; Rats; Receptors, Estrogen | 2023 |
Methyl palmitate reversed estradiol benzoate-induced endometrial hyperplasia in female rats.
Early detection and treatment of endometrial hyperplasia (EH) is mandatory for endometrial cancer prevention. Several bioactive agents of plant origin have been shown to elicit their chemotherapeutic effect against tumors and cancer via induction of mitochondrial permeability transition(mPT) pore opening. This research was therefore aimed at evaluating the potential chemopreventive effect of methyl palmitate (MP), on estradiol benzoate(EB)-induced EH, looking at the mitochondrial-mediated pathway and other possible mechanisms of action. Mitochondria were isolated using differential centrifugation. The mPT pore, mitochondrial ATPase (mATPase) activity, lipid peroxidation and cytochrome c release were determined by standard methods using spectrophotometer. Uterine interleukin 1b, MDA levels and SOD, GSH activities, were determined using commercially available kits. The uterine histological and immunohistochemical assessment of estrogen receptor (ERα), IL-1b and caspas-3 were carried out. The fibroblast cell count density was determined using histomorphometry. At all the concentrations of MP used, there was no significant induction of mPT pore opening, neither any enhancement of mATPase activity nor release of cytochrome c when compared to the control. Similar pattern of results were recorded for the Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Cell Proliferation; Cytochromes c; Endometrial Hyperplasia; Endometrium; Estradiol; Estrogen Receptor alpha; Female; Fibroblasts; Interleukin-1beta; Lipid Peroxidation; Mitochondria; Mitochondrial Proton-Translocating ATPases; Oxidative Stress; Palmitates; Rats, Wistar; Signal Transduction | 2021 |